Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Bioprinting for drug screening: A path toward reducing animal testing or redefining preclinical research?

Budharaju H., Singh RK., Kim HW.

Narrative Review on Cardiovascular Disease, published in Bioact Mater (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Bioact Mater (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40697711
PMCID
PMC12281243
DOI
10.1016/j.bioactmat.2025.07.006
Citations
2

Abstract (original English)

Bioprinting is reshaping the field of tissue regeneration and drug screening by creating physiologically accurate and scalable tissue models that reduce the limitations of conventional animal testing. It helps to minimize interspecies variability by developing complex 3D tissue structures that closely mimic the structural and functional characteristics of native tissues, ensuring high reproducibility. Furthermore, it supports more humane and sustainable preclinical testing by aligning with the ethical 3Rs principles (Replacement, Reduction and Refinement). Although bioprinting offers many advantages, its full potential in evaluating drug testing applications has yet to be harnessed. In this review, we discuss the efficacy of key bioprinting techniques in replicating the structural and functional characteristics of engineered tissues, comparing them with their native counterparts. Further, we highlight case studies demonstrating the applications of bioprinted skin, cardiac, hepatic, renal, bone, and cancer models in pharmaceutical research. The commercialization of bioprinted drug testing platforms and their integration into pharmaceutical development are also discussed. Finally, we outline key advantages, current challenges, and future directions needed to establish bioprinting as a transformative tool for preclinical drug testing, aiming to replace traditional animal models.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research